|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | The CXCR2 Antagonist, SCH-527123, Shows Antitumor Activity and Sensitizes Cells to Oxaliplatin in Preclinical Colon Cancer Models显示文摘 | Yan Ning Melissa J. Labonte Wu Zhang Pierre O. Bohanes Armin Gerger Dongyun Yang Leonor Benhaim David Paez David O. Rosenberg Kalyan C. Nagulapalli Venkata Stan G. Louie Nicos A. Petasis Robert D. Ladner Heinz-Josef Lenz | 2012 | Molecular Cancer Therapeutics2012，，6： | 1 |
| 2 | Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia显示文摘 | PAEZ J G DAVID F S | 2004 | Cancer Res2004，64，： | 1 |
| 3 | Activating mutations of the noonan syndrome-associated SHP-2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia 显示文摘 | Bentires-Alj M Paez JG David FS | 2004 | Cancer Res2004，64，24： | 1 |
| 4 | Activating mutations of the noonan syndrome-associat- ed SHP2/PTPN11 gene in human solid tumors and a-dult acute myelogenous leukemia显示文摘 | BENTIRES-ALJ M PAEZ J G DAVID F S | 2004 | Cancer Res2004，64，： | 1 |
| 5 | Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia显示文摘 | Bentires-Alj M Paez J G David F S | 2004 | Cancer Res2004，64，24： | 1 |
| 6 | Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia显示文摘 | Bentires-Alj M Paez J G David F S | 2004 | Cancer Res2004，64，24： | 1 |
| 7 | Influence of Sex on the Survival of Patients With Esophageal Cancer显示文摘 | Pierre Bohanes Dongyun Yang Ruchika S. Chhibar Melissa J. Labonte Thomas Winder Yan Ning Armin Gerger Léonor Benhaim David Paez Takeru Wakatsuki Fotios Loupakis Rita El-Khoueiry Wu Zhang Heinz-Josef Lenz | 2012 | Journal of Clinical Oncology2012，，18： | 1 |
| 8 | Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult aacute myelogenous leukemia显示文摘 | Bentires-AljM Paez JG David FS | 2004 | Cancer Res2004，64，24： | 1 |
| 9 | The CXCR2 Antagonist, SCH-527123, Shows Antitumor Activity and Sensitizes Cells to Oxaliplatin in Preclinical Colon Cancer Models显示文摘 | Yan Ning Melissa J. Labonte Wu Zhang Pierre O. Bohanes Armin Gerger Dongyun Yang Leonor Benhaim David Paez David O. Rosenberg Kalyan C. Nagulapalli Venkata Stan G. Louie Nicos A. Petasis Robert D. Ladner Heinz-Josef Lenz | 2012 | Molecular Cancer Therapeutics2012，，6： | 1 |
| 10 | Activating mutations of the Noonan syndrome-associated SHP2/PTPN11gene in human solid tumors and adult acute myelogenous leukemia显示文摘 | Bentires-Alj M Paez JG David FS Keilhack H Halmos B Naoki K | 2004 | Cancer Res2004，64，24： | 1 |
| 11 | Activating mutations of the noonan syndrome-associated SHP2/PTPNI 1 gene in human solid tumors and adult acute myelogenous leukemia显示文摘 | Bentires-Alj M Paez J G David F S | 2004 | Cancer Research2004，64，24： | 1 |
| 12 | Site-directed cysteine coupling of disulfide-containing non-antibody carrier proteins(THIOCAPs)显示文摘The development of a new generation of nonantibody protein drug delivery systems requires site-directed conjugation strategies to produce homogeneous,reproducible and scalable nanomedicines.For that,the genetic addition of cysteine residues into solvent-exposed positions allows the thiol-mediated cysteine coupling of therapeutic drugs into protein-based nanocarriers.However,the high reactivity of unpaired cysteine residues usually reduces protein stability,consequently imposing the use of more methodologically demanding purification procedures.This is especially relevant for disulfide-containing nanocarriers,as previously observed in THIOMABs.Moreover,although many protein scaffolds and targeting ligands are also rich in disulfide bridges,the use of these methodologies over emerging non-antibody carrier proteins has been completely neglected.Here,we report the development of a simple and straightforward procedure for a onestep production and site-directed cysteine conjugation of disulfide-containing non-antibody thiolated carrier proteins(THIOCAPs).This method is validated in a fluorescent C-X-C chemokine receptor 4(CXCR4)-targeted multivalent nanocarrier containing two intramolecular disulfide bridges and one reactive cysteine residue strategically placed into a solvent-exposed position(THIO-T22-GFP-H6)for drug conjugation and in a humanized alternative intended for clinical applications(T22-HSNBT-H6).Thus,we produce very stable,homogeneous and fully functional antitumoral nanoconjugates(THIO-T22-GFP-H6-MMAE and T22-HSNBT-H6-MMAE)that selectively eliminate target cancer cells via CXCR4-receptor.Altogether,the developed methodology appears as a powerful tool for the rational engineering of emerging non-antibody,cell-targeted protein nanocarriers that contain disulfide bridges together with a solvent-exposed reactive cysteine(THIOCAP).This should pave the way for the development of a new generation of stable,homogeneous and efficient nanomedicines. | Ariana Rueda Julian I.Mendoza Lorena Alba-Castellon Eloi Parladé Eric Voltà-Durán David Paez Anna Avino Ramon Eritja Esther Vázquez Antonio Villaverde Ramón Mangues Ugutz Unzueta | 2023 | Science China Materials2023，66，10： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员